Previous 10 | Next 10 |
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 PR Newswire Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and reliability profile Initia...
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones PR Newswire Reported positive early clinical data for allogeneic myeloma cell therapy P-BCMA-ALLO1 at ASH 2023 supporting potential of T SCM -rich allogeneic CAR-T to ...
2023-12-21 08:06:15 ET Summary Poseida Therapeutics is an oncology-focused biotech specializing in the development of cell therapies, particularly CAR T-cell approaches for multiple myeloma and acute leukemia. They have demonstrated promising early results in their clinical trials...
2023-12-12 08:39:32 ET Losers: Achieve Life Sciences ( ACHV ) -24% announces participation at upcoming investor conferences. Clearmind Medicine CMND -13% files for $50M mixed shelf . Oracle Corp. ORCL -10% after Q2 earnings release . Acurx Pharmaceu...
2023-12-11 16:53:07 ET DENVER, Colo., Dec. 11, 2023 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Marker Therapeutics, Inc. (NASDAQ: MRKR), Poseida Therapeutics (NASDAQ: PSTX), Assure Holdings (NASDAQ: IONM), Jet AI (NASDAQ: JTAI), and NextPlay Techn...
2023-12-11 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Veru, Kodiak S...
2023-12-11 09:56:01 ET DENVER, Colo., Dec. 11, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Pasithea Therapeutics Corp (NASDAQ: KTTA), Poseida Therapeutics, Inc. (NASDAQ: PSTX), Onconova Therapeutics I...
2023-12-11 09:08:24 ET DENVER, Colo., Dec. 11, 2023 ( www.247marketnews.com )- Companies mentioned include Macy’s Inc (NYSE: M), Siyata Mobile (NASDAQ: SYTA), Assure Holdings Corp (NASDAQ: IONM), and Poseida Therapeutics, Inc. (NASDAQ: PSTX). Macy’s Inc (NYSE: M) is tr...
2023-12-11 08:02:38 ET DENVER, Colo., Dec 11, 2023 ( www.247marketnews.com )- Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported, Sunday evening, early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-r...
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting PR Newswire 82% ORR and deep clinical responses from off-the...
News, Short Squeeze, Breakout and More Instantly...
Poseida Therapeutics Inc. Company Name:
PSTX Stock Symbol:
NASDAQ Market:
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeti...
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting PR Newswire Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic rang...
2024-05-01 14:28:11 ET A California-based %Biotech company is turning heads on Wednesday after it announced that it entered into a research collaboration and license agreement with Astellas Pharma’s Xyphos Biosciences subsidiary. Shares of %PoseidaTherapeutics (Nasdaq: $P...